ZURICH,Dec. 30,2024 -- Amcor (NYSE: AMCR,ASX: AMC),a global leader in developing and producing responsible packaging solutions,announced today it completed the sale of its 50% interest in Bericap North America (BCNA) for $122 million on December 27,with the proceeds used to reduce debt.

Amcor completed the sale of its 50% interest in Bericap North America (BCNA) for $122 million,with the proceeds used to reduce debt.
Fiscal 2024 total sales for the joint venture were approximately $190 million and adjusted EBIT was approximately $19 million,both of which were previously fully consolidated under Amcor's Rigid Packaging business. Adjusted net income attributable to Amcor for fiscal 2024 was approximately $8 million. Net of the resulting reduction in interest expense,the transaction is not expected to have an impact on Amcor's financial outlook for fiscal 2025.
About Amcor
Amcor is a global leader in developing and producing responsible packaging solutions across a variety of materials for food,beverage,pharmaceutical,medical,home and personal-care,and other products. Amcor works with leading companies around the world to protect products,differentiate brands,and improve supply chains. The Company offers a range of innovative,differentiating flexible and rigid packaging,specialty cartons,closures and services. The company is focused on making packaging that is increasingly recyclable,reusable,lighter weight and made using an increasing amount of recycled content. In fiscal year 2024,41,000 Amcor people generated $13.6 billion in annual sales from operations that span 212 locations in 40 countries. NYSE: AMCR; ASX: AMC
www.amcor.comILinkedInIYouTube
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
©copyright 2009-2020 Singapore Info Map